Application of alpha-fetoprotein and IL-6 in prognostic prediction of patients with hepatitis B related liver failure
10.3969/j.issn.1006-2483.2024.03.033
- VernacularTitle:甲胎蛋白、IL-6在乙型肝炎相关肝衰竭患者预后预测中的应用
- Author:
Ling YAO
1
,
2
;
Chao CHEN
1
,
2
Author Information
1. Department of Infection , The Second People'
2. s Hospital of Yibin , Yibin , Sichuan 644000 , China
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Liver failure;
Alpha-fetoprotein;
Interleukin-6;
Prognostic prediction
- From:
Journal of Public Health and Preventive Medicine
2024;35(3):141-144
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the application value of alpha-fetoprotein (AFP) and interleukin-6 (IL-6) in prognosis prediction of hepatitis B virus (HBV) associated liver failure. Methods A total of 135 patients with HBV-related liver failure who underwent treatment at the Infection Department of the Second People's Hospital of Yibin City from July 2020 to June 2022 were selected as the study subjects (observation group). Additionally, 100 patients who underwent physical examination in the hospital during the same period with normal indicators were selected as the control group. Serum levels of AFP and IL-6 were compared between the two groups. Factors influencing the prognosis of HBV-related liver failure were analyzed. Multiple logistic regression was used to analyze the risk factors affecting the prognosis of HBV-related liver failure patients. Results The levels of serum AFP and IL-6 in the control group were lower than those in the control group, and the difference was statistically significant (P<0.05). The two groups showed statistically significant differences in clinical symptoms such as hepatic encephalopathy, hepatorenal syndrome, ascites, and disease type (P<0.05). Multiple logistic regression analysis showed that the clinical symptoms of hepatic encephalopathy, hepatorenal syndrome, ascites and AFP≥25 μg/L and IL-6>10.0 pg/mL were risk factors affecting the prognosis of HBV-related liver failure. Conclusion Serum AFP and IL-6 can predict the prognosis of patients with HBV-related liver failure, which is worthy of clinical study.
